Page 145 - 《中国药房》2026年10期

tive breast cancer[J]. N Engl J Med，2019，380（7）： tor receptor 2-positive advanced or metastatic breast can‐
617-628. cer：an open-label，randomized，phase Ⅲ trial（TULIP）[J].
[15] EMENS L A，ESTEVA F J，BERESFORD M，et al. Trastu‐ J Clin Oncol，2025，43（5）：513-523.
zumab emtansine plus atezolizumab versus trastuzumab [25] ANDRE F，HAMILTON E P，LOI S，et al. DESTINY-
emtansine plus placebo in previously treated，HER2-posi‐ Breast07：dose-expansion interim analysis of T-DXd
tive advanced breast cancer（KATE2）：a phase 2，multicen‐ monotherapy and T-DXd+pertuzumab in patients with pre‐
tre，randomised，double-blind trial[J]. Lancet Oncol，2020， viously untreated HER2+mBC[J]. J Clin Oncol，2024，42
21（10）：1283-1295. （Suppl. 16）：1009.
[16] TOLANEY S M，TAYOB N，DANG C，et al. Adjuvant [26] BARDIA A，HU X C，DENT R，et al. Trastuzumab derux‐
trastuzumab emtansine versus paclitaxel in combination tecan after endocrine therapy in metastatic breast cancer
with trastuzumab for stage Ⅰ HER2-positive breast cancer [J]. N Engl J Med，2024，391（22）：2110-2122.
（ATEMPT）：a randomized clinical trial[J]. J Clin Oncol， [27] LI J J，WANG Z H，CHEN L，et al. Efficacy and safety of
2021，39（21）：2375-2385 neoadjuvant SHR-A1811 with or without pyrotinib in
[17] KROP I E，IM S A，BARRIOS C，et al. Trastuzumab em‐ women with locally advanced or early HER2-positive
tansine plus pertuzumab versus taxane plus trastuzumab breast cancer：a randomized，open-label，phase Ⅱ trial[J].
plus pertuzumab after anthracycline for high-risk human Ann Oncol，2025，36（6）：651-659.
epidermal growth factor receptor 2-positive early breast [28] JI C C，LI F，YUAN Y，et al. Novel anti-HER2 antibody-
cancer：the phase Ⅲ KAITLIN study[J]. J Clin Oncol， drug conjugates versus T-DM1 for HER2-positive meta‐
2022，40（5）：438-448. static breast cancer after tyrosine kinase inhibitors treat‐
[18] RUGO H S，BARDIA A，MARMÉ F，et al. Sacituzumab ment[J]. Oncologist，2023，28（10）：e859-e866.
govitecan in hormone receptor-positive/human epidermal [29] GOULD B J，BOROWITZ M J，GROVES E S，et al.
growth factor receptor 2-negative metastatic breast cancer Phase Ⅰ study of an anti-breast cancer immunotoxin by
[J]. J Clin Oncol，2022，40（29）：3365-3376. continuous infusion：report of a targeted toxic effect not
[19] ANDRÉ F，HEE PARK Y，KIM S B，et al. Trastuzumab predicted by animal studies[J]. JNCI J Natl Cancer Inst，
deruxtecan versus treatment of physician’s choice in pa‐ 1989，81（10）：775-781.
tients with HER2-positive metastatic breast cancer [30] TARANTINO P，TOLANEY S M. Detecting and mana-
（DESTINY-Breast02）：a randomised，open-label，multi‐ ging T-DXd-related interstitial lung disease：the five “S”
centre，phase 3 trial[J]. Lancet，2023，401（10390）：1773- rules[J]. JCO Oncol Pract，2023，19（8）：526-527.
1785. [31] NAKADA T，SUGIHARA K，JIKOH T，et al. The latest
[20] HURVITZ S A，HEGG R，CHUNG W P，et al. Trastu‐ research and development into the antibody-drug conju‐
zumab deruxtecan versus trastuzumab emtansine in pa‐ gate，[fam- ] trastuzumab deruxtecan（DS-8201a），for
tients with HER2-positive metastatic breast cancer：up‐ HER2 cancer therapy[J]. Chem Pharm Bull，2019，67（3）：
dated results from DESTINY-Breast03，a randomised， 173-185.
open-label，phase 3 trial[J]. Lancet，2023，401（10371）： [32] GUPTA A，DRAGO J Z，CHANDARLAPATY S. ADCs
105-117. or：how I learned to stop worrying and love chemotherapy
[21] WANG X J，LI W，YIN Y M，et al. Primary results of [J]. Cancer Discov，2023，13（4）：817-818.
ELAINA：a randomized，multicenter，open-label，phase Ⅲ [33] BAROK M，JOENSUU H，ISOLA J. Trastuzumab emtan‐
study of the efficacy and safety of trastuzumab emtansine sine：mechanisms of action and drug resistance[J]. Breast
vs. lapatinib plus capecitabine in Chinese patients with Cancer Res，2014，16（2）：209.
HER2-positive locally advanced or metastatic breast can‐ [34] JUNUTULA J R，RAAB H，CLARK S，et al. Site-specific
cer who have received prior trastuzumab-based therapy[J]. conjugation of a cytotoxic drug to an antibody improves
Transl Breast Cancer Res，2023，4：3. the therapeutic index[J]. Nat Biotechnol，2008，26（8）：
[22] BARDIA A，JHAVERI K，IM S A，et al. Datopotamab de‐ 925-932.
ruxtecan versus chemotherapy in previously treated inope- [35] GOLDENBERG D M，SHARKEY R M. Sacituzumab go‐
rable/metastatic hormone receptor-positive human epider‐ vitecan，a novel，third-generation，antibody-drug conjugate
mal growth factor receptor 2-negative breast cancer：pri‐ （ADC）for cancer therapy[J]. Expert Opin Biol Ther，
mary results from TROPION-breast01[J]. J Clin Oncol， 2020，20（8）：871-885.
2025，43（3）：285-296. [36] ROSENBERG J E，O’DONNELL P H，BALAR A V，et
[23] HU X C，ZHANG Q Y，WANG L P，et al. ACE-Breast- al. Pivotal trial of enfortumab vedotin in urothelial carci‐
02：a randomized phase Ⅲ trial of ARX788 versus lapa‐ noma after platinum and anti-programmed death 1/pro‐
tinib plus capecitabine for HER2-positive advanced breast grammed death ligand 1 therapy[J]. J Clin Oncol，2019，37
cancer[J]. Signal Transduct Target Ther，2025，10（1）：56. （29）：2592-2600.
[24] TURNER N，SAURA C，AFTIMOS P，et al. Trastuzumab （收稿日期：2026-01-12 修回日期：2026-05-09）
duocarmazine in pretreated human epidermal growth fac‐ （编辑：陈 宏）

中国药房 2026年第37卷第10期 China Pharmacy 2026 Vol. 37 No. 10 · 1375 ·